LIXTE Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton cancer therapy company. Its primary asset is LB-100, a small molecule inhibitor of protein phosphatase 2A (PP2A) being tested in clinical trials for ovarian clear cell carcinoma, metastatic MSS colon cancer, and advanced soft tissue sarcoma. The company is also the majority shareholder of Liora Technologies Europe Ltd., which is developing the LiGHT System, an electronically controlled proton therapy system for treating tumors.
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-014052 | EDGAR | 97K words |
| 2025-03-24 | 2024-12-31 | 0001641172-25-000208 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001493152-24-010427 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001493152-23-009386 | EDGAR | — |
| 2022-03-21 | 2021-12-31 | 0001493152-22-007327 | EDGAR | — |
| 2021-03-26 | 2020-12-31 | 0001493152-21-006882 | EDGAR | — |
| 2020-03-25 | 2019-12-31 | 0001493152-20-004697 | EDGAR | — |
| 2019-03-25 | 2018-12-31 | 0001493152-19-003870 | EDGAR | — |
| 2018-03-23 | 2017-12-31 | 0001493152-18-003806 | EDGAR | — |
| 2017-03-29 | 2016-12-31 | 0001493152-17-002940 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001493152-25-021941 | EDGAR | 50K words |
| 2025-08-07 | 2025-06-30 | 0001641172-25-022517 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001641172-25-009575 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044810 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001493152-24-030757 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018337 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001493152-23-040115 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001493152-23-027269 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001493152-23-016069 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001493152-22-030878 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001493152-22-021832 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001493152-22-012779 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001493152-26-011829 | EDGAR | 1K words |
| 2026-03-10 | 0001493152-26-009526 | EDGAR | — |
| 2026-02-18 | 0001493152-26-007268 | EDGAR | — |
| 2025-12-31 | 0001493152-25-029778 | EDGAR | — |
| 2025-12-23 | 0001493152-25-028999 | EDGAR | — |
| 2025-12-22 | 0001493152-25-028850 | EDGAR | — |
| 2025-12-11 | 0001493152-25-027219 | EDGAR | — |
| 2025-11-25 | 0001493152-25-024996 | EDGAR | — |
| 2025-09-11 | 0001641172-25-027109 | EDGAR | — |
| 2025-09-04 | 0001641172-25-026448 | EDGAR | — |
239 total filings indexed. 207 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001335105 |
| Ticker | LIXT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.lixte.com |
| Listed | 2007-09-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report